- Home
- PENG vs SGP Comparison
PENG vs SGP Comparison
Compare PENG & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | SGP |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 959.2M | 932.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PENG | SGP |
|---|---|---|
| Price | $44.70 | $24.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $27.78 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.2M | 55.7K |
| Earning Date | 04-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.55 | N/A |
| Revenue Next Year | $16.14 | N/A |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $20.15 |
| 52 Week High | $46.75 | $30.56 |
Technical Indicators
Market Signals| Indicator | PENG | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 87.36 | 50.07 |
| Support Level | $22.13 | $20.95 |
| Resistance Level | N/A | $26.55 |
| Average True Range (ATR) | 2.90 | 1.49 |
| MACD | 1.31 | 0.11 |
| Stochastic Oscillator | 88.41 | 62.24 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.